Investors & Media
Dedicated to delivering long-term investment value.
Featured News: CSL and uniQure Win 2023 Prix Galien USA Award
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
-
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Stock Information
Updated stock ticker information for uniQure
- NASDAQ:
- Price:
- Change:
- Volume:
(Updated every 15 minutes)
SEC Filings
Security and exchange commission filings for uniQure, including quarterly and annual reports
Learn MoreUpcoming Webcasts
No webcasts scheduled. Check back soon.
Webcast Archive
-
2023 Cantor Global Healthcare Conference
View Webcast
9:45AM ET - 10:15AM ET -
Wells Fargo 2023 Healthcare Conference
View Webcast
2:15PM ET-2:50PM ET -
uniQure Huntington's Disease Program Update: AMT-130
View Webcast
8:30 a.m. ET
Investor Presentations
-
Huntington's Disease Program Update AMT-130 – Webcast Presentation
View Presentation -
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements
View Presentation -
ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions
View Presentation -
EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B
View Presentation -
ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders
View Presentation